Online, United States
Lectures & Conferences
CRISPR is one of the most powerful discoveries of the last decade, and we are now heralding in the era of gene editing.
In the time since its discovery, CRISPR has rapidly become an established tool in the genomics toolbox. Now the question is: What next?
The CRISPR 2.0 Summit is devoted to showcasing only the latest and greatest innovations by uncovering how the next generation of CRISPR tools are radically enhancing efficacy, minimizing off-target effects and enabling efficient delivery to specific tissues to ensure you stay at the forefront of this rapidly exploding field.
Discover the promise of novel Cas variants, base and prime editing approaches, innovative delivery mechanisms, and the applications of these next generation tools through learnings from CRISPR clinical trials and new and unpublished data.
Don't get left behind. Join 100+ leading pharma and biotech companies pioneering CRISPR-based therapeutics into the clinic to usher in the next generation of safe, targeted and effective genome editing.
Conference Only (1st Release - Pay by July 30): USD 1599.0,
Conference Only (2nd Release - Pay by August 27): USD 1699.0,
Conference Only (3rd Release - Pay by September 24): USD 1799.0,
Conference Only (4th Release - Pay by October 22): USD 1899.0,
Conference Only (Standard Rate): USD 1999.0
Speakers: John Murphy, Chief Scientific Officer, Arbor Biotechnologies, Roy Ziblat, Scientific Manager, Arbor Biotechnologies, Marco Weinberg, Vice President, Research and Development, AskBio, Roberto Nitsch, Director, AstraZeneca, Joseph Miano, J. Harold Harrison, MD, Distinguished University Chair in Vascular Biology, Augusta University, Jacob Layer, Senior Scientist, Group Leader, eGenesis Bio, Pankaj Mandal, Senior Staff Fellow, Office of Tissues and Advanced Therapies, Division of Cellular and Gene Therapies, FDA/CBER, Kalina Paunovska, Postdoctoral Scholars, Georgia Institute of Technology, Dahlman Lab, Danilo Maddalo, Senior Scientist, Genentech, Beeke Wienert, Senior Scientist, Research, Graphite Bio, Danny Dever, Head of Discovery Research, Graphite Bio, Jane Grogan, Chief Scientific Officer, Graphite Bio, Ben Kleinstiver, Assistant Professor, Harvard Medical School and Mass General Hospital, Sean Burns, Vice President, Disease Biology, Intellia Therapeutics, Triparna Sen, Assistant Attending, Memorial Sloan Kettering Cancer Center, Gregory Cost, Senior Director of Biology, Metagenomi, Jyun-Liang "Aaron" Lin, Scientist II, Metagenomi, Andrew Anzalone, Head of Prime Editing Platforms, Prime Medicine, Brett Staahl, Vice President Platform, Co- Founder, Scribe Therapeutics, Niren Murthy, Professor, Bioengineering, University of California at Berkeley